NOMAD POWER SOLUTIONS, INC.

NMAD
About the company

Lixte Biotechnology Holdings, Inc. develops utility-scale mobile energy storage systems on providing transportable solutions. It offers plug-and-play battery storage systems integrated into specially designed and patent-pending mobile energy storage systems and docking systems.

Country: United StatesPrice: $2.35Market Cap: $37.8M

Investment snapshot

6%positive consensus
Scored 1d ago

Positive

1

BUY / PASS

Neutral / negative

2 / 13

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Key risk

No clean pass — all 16 investors flag at least one profitability criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #2572 (Top 83%)PASSFAILFAILFAILFAILFAILFAILFAILFAILNEUTRALFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

Annual history · FY 2025 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Market data at 2026-11-01

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-31

Score computed: 2026-11-14

TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-08-14

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Profitability0% pass✓ 2✗ 33▾

      No clean pass — all 16 investors flag at least one profitability criterion

      Positive EPS (10 years)0/19 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)0/19 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)-177.3%
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)
      ✗BuffettStable or rising over 10 years
      Free Cash Flow Proxy
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROE-37.3%
      ✗Lynch> 15%
      EBIT / Enterprise Value-15.6%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-15.6%, ROC=-96.0%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets-47.74%
      ✗PiotroskiROA > 0
      ROA Change YoY-313.05% -> -47.74% (delta: +265.31%)
      ✓PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=-24.11%, ROA=-47.74%
      ✓PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY
      ✗PiotroskiImproved YoY
      Pre-Tax Income / Revenue
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity-37.3%
      ✗Dreman> 12%
      Margin of SafetyP/B=2.1x
      ✗PabraiP/B < 1.5 or P/E < 15
      Return on Equity-207.9% (3-yr avg)
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic Value
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency0/18 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue
      ✗Ackman>= 15%
      Net Income / Shareholders Equity-37.3%
      ✗Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend
      ✗TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trend
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization-23.59%; #4654/6340 (top 73.4%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets
      ✗AsnessTop 30% of eligible cross-section
      Net income / positive book equity-37.33%; #4034/5226 (top 77.2%)
      ✗AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-0.8898; #5226/5884 (top 88.8%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years0/10 years positive
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Valuation0% pass✗ 28▾

      All 13 investors flag NMAD's valuation

      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio2.1x
      ✗Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise Value-15.6%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-15.6%, ROC=-96.0%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      Price / Book Value per Share2.1x
      ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
      Valuation Reasonableness
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF Yield
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical AverageP/B=2.1x
      ✗MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic Value
      ✗Marks>= 20% below intrinsic value
      Price / FCF per Share
      ✗Ackman<= 25
      Price vs. Trailing Low258% of trailing low ($0.91)
      ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization-23.59%; #4654/6340 (top 73.4%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization+0.6319; #2413/6449 (top 37.4%)
      ✗AsnessTop 30% of eligible cross-section
      Price / Diluted EPS
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per Share2.14x
      ✗SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change
      ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization
      ✗OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date-62.40%; #5459/6202 (top 88.0%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Cash Flow0% pass✓ 1✗ 11▾

      No clean pass — all 10 investors flag at least one cash flow criterion

      Free Cash Flow Proxy
      ✗BuffettPositive and growing
      FCF Positive and Growing
      ✗LynchPositive and growing
      Operating Cash Flow$-3.1M
      ✗PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=-24.11%, ROA=-47.74%
      ✓PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      P/E or FCF Yield
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive
      ✗MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap
      ✗Ackman>= 4%
      Price / FCF per Share
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency1/16 years positive
      ✗SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures
      ✗Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization
      ✗OshaughnessyTop 10% of eligible cross-section
    • Growth0% pass✓ 1✗ 12▾

      No clean pass — all 8 investors flag at least one growth criterion

      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue GrowthN/A (no inventory)
      ✓LynchInventory growth < Revenue growth
      EPS Growth Direction
      ✗DremanPositive over recent years
      EPS CAGR
      ✗Dreman> 5% annualized
      Positive Net Income Frequency0/18 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth
      ✗Ackman>= 5%
      Positive EPS Growth Frequency
      ✗AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trend
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR
      ✗SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
    • Verdicts7% pass✓ 1✗ 14▾

      Split decision: 13 FAIL · 2 NEUTRAL · 1 PASS

      Overall verdict
      ✗GrahamFAIL (1/9)✗BuffettFAIL (0/9)✗LynchFAIL (1/7)✗GreenblattRank #2572✓PiotroskiPASS (F-Score 4)✗DremanFAIL (1/11)✗MungerFAIL (1/4)✗PabraiFAIL (0/3)✗AkreFAIL (0/6)✗MarksFAIL (0/5)✗AckmanFAIL (0/9)✗TempletonFAIL (1/8)✗SleepFAIL (0/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (0/6)✗SchlossFAIL (1/7)•OshaughnessyNEUTRAL (Not ranked)
    • Debt & Leverage8% pass✓ 3✗ 12▾

      11 of 12 flag NMAD's debt & leverage — Graham, Buffett, Lynch +8 more

      LT Debt vs Net Current Assets
      ✗GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest Coverage
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / Equity
      ✗Lynch< 0.33
      Cash - Long-term Debt
      ✗LynchPositive preferred
      LT Debt / Total Assets Change0.00% -> 0.00%
      ✓PiotroskiDecreased YoY
      Current Assets / Current Liabilities12.87
      ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
      Total Debt / Shareholders' Equity
      ✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
      Debt Levels
      ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDAIC=-557.7x, D/EBITDA=N/A (D&A unavailable)
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity
      ✗Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)
      ✗AsnessTop 30% of eligible cross-section
    • Efficiency25% pass✓ 3✗ 8▾

      6 of 8 flag NMAD's efficiency — Buffett, Greenblatt, Piotroski +3 more

      Current Ratio12.87
      ✓Graham>= 2.0
      ROIC (3-5 yr avg)
      ✗Buffett> 10%
      ROIC - WACC
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)-96.0%
      ✗Greenblatt> 25%
      Current Ratio Change YoY3.60 -> 3.88
      ✓PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY
      ✗PiotroskiImproved YoY
      Current Assets / Current Liabilities12.87
      ✓Dreman> 1.5
      Return on Invested Capital
      ✗Munger> 15%
      ROIC (high and growing)FY2023: ROIC=unavailable; FY2024: ROIC=unavailable; FY2025: ROIC=unavailable
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROIC
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)
      ✗SleepROIC > 12% in a majority of years

    Business & financials

    Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Pharmaceutical Products
    SIC Sector: Chemicals & Pharmaceuticals
    Size: Micro Cap($37.8M)
    Revenue: N/A
    Net Income: $6.1M-69.5% YoY

    Financial Snapshot

    Operating Margin--
    Return on Equity-62.9%
    Debt / Equity--
    Current Ratio3.88
    EPS (Diluted)$-1.26

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

    MetricTTM · 2026-06-30

    2025-07-01 – 2026-06-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, net income, operating income, ebit, interest expense.

    Q2 FY 2026

    2026-04-01 – 2026-06-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow.

    Q1 FY 2026

    2026-01-01 – 2026-03-31

    Sources
    FY 2025
    Sources
    • 10-K · 2026-03-31
    FY 2024
    Sources
    • 10-K · 2025-03-24
    FY 2023
    Sources
    • 10-K · 2024-03-19
    FY 2022
    Sources
    • 10-K · 2023-03-29
    FY 2021
    Sources
    • 10-K · 2022-03-21
    Market Cap$37.8Mcurrent----$32.7Mest.$5.6Mest.$4.7Mest.$13.2Mest.$266.7Mest.
    Revenue----------------
    Operating Income-$8.0M↓159%-$2.3M↓203%-$2.0M↓181%-$5.1M↓43%-$3.6M↑30%-$5.1M↑19%-$6.3M↑6%-$6.7M
    Net Income-$8.9M↓189%-$2.3M↓202%-$2.0M↓180%-$6.1M↓70%-$3.6M↑30%-$5.1M↑19%-$6.3M↑6%-$6.7M
    EPS (Diluted)--$-0.16↑45%$-0.18↑38%$-1.26↑21%$-1.59↑40%$-2.66↑33%$-3.99↓698%$-0.50
    Gross Margin————————
    Operating Margin————————
    ROE-37.3%↑92%——-62.9%↑85%-433.5%↓240%-127.3%↓4%-122.2%↑13%-140.5%
    Total Debt----------------
    Shareholders' Equity$23.9M↑3570%$23.9M↑3570%$7.9M↑585%$9.7M↑1068%$827.2K↓79%$4.0M↓23%$5.2M↑8%$4.8M
    Current Ratio12.87↑598%12.87↑598%2.783.88↑8%3.60↓74%13.73↓2%14.05↓16%16.81
    Debt / Equity————————
    Operating Cash Flow-$5.5M↓109%-$1.6M↓231%-$1.8M↓222%-$3.1M↑3%-$3.2M↑26%-$4.3M↑7%-$4.6M↓11%-$4.1M
    Free Cash Flow----------------

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Pharmaceutical Products

    NMAD vs Peers — Financial Grading

    RevenueN/A
    Net Income$6.1MMedian
    ROE-62.9%Bottom 25%
    D/E—
    Op. Margin—
    Curr. Ratio3.88Top 25%
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    Merck & Co., Inc.MRK$364.3B$147.76$65.0B$18.3B34.7%0.94—1.542/95/94/70/3F-Score 41/11
    ABBOTT LABORATORIESABT$188.0B$108.52$44.3B$6.5B12.5%0.2518.2%1.583/94/92/71/3F-Score 53/11
    BRISTOL MYERS SQUIBB COBMY$129.7B$63.43$48.2B$7.1B38.2%2.4419.4%1.262/91/93/71/3F-Score 85/11
    BIO-TECHNE CorpTECH$11.4B$72.80$1.2B$73.4M3.8%—8.4%3.464/93/93/70/3F-Score 54/11
    REPLIGEN CORPRGEN$10.7B$167.79$738.3M$48.9M2.3%0.267.5%8.373/92/93/70/3F-Score 75/11
    IONIS PHARMACEUTICALS INCIONS$4.8B$29.06$943.7M$381.4M-78.0%3.60-40.4%3.833/91/91/70/3F-Score 43/11
    NEOGEN CORPNEOG$2.5B$11.23$870.4M$7.9M-0.4%0.76-2.5%3.823/91/92/70/3F-Score 64/11
    Pharvaris N.V.PHVS$2.4B$33.36—$206.4M-64.8%0.00——0/90/92/70/3F-Score 22/11